|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2011 (US)
|
|
gptkbp:ATCCode
|
gptkb:B01AF01
|
|
gptkbp:bioavailability
|
80-100%
|
|
gptkbp:brand
|
gptkb:Xarelto
|
|
gptkbp:CASNumber
|
366789-02-8
|
|
gptkbp:contraindication
|
active pathological bleeding
severe hypersensitivity to rivaroxaban
|
|
gptkbp:developedBy
|
gptkb:Bayer
gptkb:Johnson_&_Johnson
|
|
gptkbp:drugClass
|
gptkb:anticoagulant
factor Xa inhibitor
|
|
gptkbp:eliminationHalfLife
|
5-9 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasBoxedWarning
|
spinal/epidural hematoma risk
increased risk of thrombotic events after premature discontinuation
|
|
gptkbp:hasInChIKey
|
GQSPXLAQXDMVFI-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
gptkb:C19H18ClN3O5S
|
|
gptkbp:hasPatentExpiry
|
2024 (US)
|
|
gptkbp:hasSMILES
|
CC1=NN(C2=C1C=CC(=C2)Cl)C(=O)C3=CC=C(C=C3)S(=O)(=O)NC(=O)O
|
|
gptkbp:hasUNII
|
9N1LH5M5MR
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB01486
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
direct factor Xa inhibitor
|
|
gptkbp:metabolism
|
gptkb:CYP3A4
gptkb:CYP2J2
|
|
gptkbp:molecularWeight
|
435.88
|
|
gptkbp:name
|
gptkb:Rivaroxaban
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
92-95%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL112911
gptkb:DB01486
9875401
D08917
8056267
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
bleeding
dizziness
dyspepsia
|
|
gptkbp:status
|
true
|
|
gptkbp:synonym
|
gptkb:BAY_59-7939
|
|
gptkbp:usedFor
|
prevention of venous thromboembolism after hip or knee replacement surgery
treatment of deep vein thrombosis
treatment of pulmonary embolism
prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
|
|
gptkbp:bfsParent
|
gptkb:DMT
|
|
gptkbp:bfsLayer
|
7
|